News

ROCK inhibitor Bravyl shows early signs of efficacy for ALS

Bravyl, an investigational oral therapy from Woolsey Pharmaceuticals, was safe and lowered levels of the nerve damage biomarker neurofilament light chain (NfL) in people with amyotrophic lateral sclerosis (ALS), according to new data from a Phase 2a clinical trial. The medication also showed early signs of slowing disease…

Radicava found to prolong survival in real-world analysis

Adding Radicava (edaravone) to riluzole prolongs survival of amyotrophic lateral sclerosis (ALS) patients by more than three months relative to riluzole alone, according to analyses of real-world data from the ALS/MND Natural History Study Consortium database. These and other Radicava-related findings were presented by the therapy’s developer…

COYA 302 slows disease progression, lowers biomarkers: Trial

COYA 302, Coya Therapeutics’ experimental immune-modulating combination therapy, safely slows disease progression and reduces levels of disease biomarkers in people with amyotrophic lateral sclerosis (ALS). That’s according to the now-published results from a small proof-of-concept Phase 1 clinical trial (NCT06307301) that tested the therapy in four ALS…

ALS scholarship program to help students who have lost parents

The nonprofit organization ALS Northwest has partnered with the Oregon State Treasury to establish a college scholarship program through the state-administered Oregon College Savings Plan for students who have lost parents or guardians to amyotrophic lateral sclerosis (ALS). ALS Northwest will administer the Elinore Nudelman ALS College…

Eli Lilly to develop, market ALS therapy for UNC13A function

Eli Lilly has acquired the global exclusive rights to develop and market QRL-204, QurAlis’ investigational therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) that’s designed to restore UNC13A function in nerve cells. UNC13A is an essential regulator of neurotransmitter release at synapses, a key process…